Melanoma in Solid Organ Transplant Recipients

González‐Cruz, Carlos; Ferrándiz-Pulido, Carla; Briones, Vicente García-Patos

doi:10.1016/j.adengl.2021.01.011

Cited by 3 publications

(10 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Начиная с первых трансплантаций донорских органов был отмечен повышенный риск развития рака различных локализаций у реципиентов солидных органов [1,2,[6][7][8][9][10]. Большинство авторов приходят к заключению, что в течение следующего десятилетия злокачественные новообразования станут ведущей причиной смерти у реципиентов солидных органов [3,4,[11][12][13].…”

Section: эпидемиологияunclassified

“…Существуют три основных механизма развития злокачественных новообразований у реципиентов солидных органов: развитие злокачественного новообразования de novo; трансплантация органа, содержащего злокачественное новообразование (первичное или метастаз); прогрессирование существовавшего до трансплантации у реципиента неопластического процесса [8,18]. По мнению многих авторов, существует ряд факторов, связанных с развитием злокачественных новообразований у реципиентов солидных органов, среди которых: характер и продолжительность иммуносупрессивной терапии, сопутствующая вирусная инфекция, воздействие солнца (для рака кожи), наличие в анамнезе предтрансплантационного диализа у реципиентов почки (риск развития почечно-клеточного рака связан с формированием приобретенного поликистоза почек, возникающего у пациентов, длительно находящихся на гемодиализе), а также эпизоды острого отторжения [1,7,11,[16][17][18][19][20][21][22].…”

Section: патогенезunclassified

“…Иммуносупрессивная терапия, направленная против Т-лимфоцитов (антитимоцитарный глобулин), предрасполагает к развитию PTLD, индуцированных вирусом Эпштейна-Барр [7,15]. Напротив, терапия антителами, нацеленными на В-лимфоциты (ритуксимаб), не приводит к увеличению частоты развития злокачественных новообразований [8].…”

Section: патогенезunclassified

“…С учетом неуклонно возрастающего количества трансплантаций солидных органов во всем мире (только за 2020 год в мире выполнено 113 363 трансплантации солидных органов) и постепенного увеличения продолжительности жизни реципиентов донорских органов актуальность изучения злокачественных новообразований будет только возрастать. Вопросы развития онкозаболеваний у этой категории достаточно подробно освещены в иностранной литературе, тогда как отечественных источников мы не нашли [1][2][3][4][5][6][7][8][9][10][11][12][13]30].…”

Section: Introductionunclassified

See 3 more Smart Citations

Post-transplant malignancies in solid organ recipients: development mechanisms and risk factors

Nikulin

Пашков

Якунин

2021

RJTAO

View full text Add to dashboard Cite

According to the International Agency for Research on Cancer, there were an estimated 19,292,789 new cancer cases in various localizations and 9,958,133 cancer deaths worldwide in 2020. These frightening figures clearly show that malignancies among the population is a pressing matter. The risk of post-transplant malignancy in solid organ recipients is 2–6-times higher than in the general population. Given the steadily increasing number of solid organ transplants worldwide and the gradual increase in life expectancy among organ recipients, studying the issues concerning risk factors and development mechanisms becomes a crucial task.

show abstract

Section: эпидемиологияunclassified

Section: патогенезunclassified

Section: Introductionunclassified

See 2 more Smart Citations

Post-transplant malignancies in solid organ recipients: development mechanisms and risk factors

Nikulin

Пашков

Якунин

2021

RJTAO

View full text Add to dashboard Cite

show abstract

“…Melanoma has a high risk of metastasis. Current treatment options for melanoma primarily consist of surgical resection, radiotherapy and chemotherapy; however, these methods are only effective for tumors at early stages (2). Once metastasis occurs, the median survival time is only 6-9 months (3).…”

Section: Introductionmentioning

confidence: 99%

UCHL3 plays an important role in the occurrence and development of melanoma

Zhou

Liu

et al. 2021

Oncol Lett

View full text Add to dashboard Cite

It has been reported that ubiquitin C-terminal hydrolase-L3 (UCHL3) plays an important role in cancer development; however, the role of UCHL3 in melanoma remains unclear. The present study aimed to investigate the role of ubiquitin C-terminal hydrolase-L3 (UCHL3) and determine its underlying molecular mechanisms in melanoma occurrence and development using in vitro studies. Reverse transcription-quantitative PCR analysis was performed to detect UCHL3 mRNA expression. The MTT assay was performed to assess cell proliferation. Cell apoptosis was analyzed via flow cytometry and the TUNEL assay. Cell ultrastructure was observed via transmission electron microscopy. LC3B protein expression was detected via cellular immunofluorescence, while neural precursor cell-expressed developmentally downregulated protein 8 (NEDD8) and LC3 protein expression levels, and NEDD8 ubiquitination were detected via western blot analysis. The results demonstrated that transfection with small interfering (si)RNA-UCHL3 significantly suppressed cell proliferation, whereas apoptosis was significantly enhanced, as well as autophagy, autophagosome formation and LC3B protein expression. In addition, NEDD8 protein expression and autophagosome numbers significantly decreased, while the LC3II/LC3I ratio significantly increased. NEDD8 knockdown via transfection with si-NEDD8 had similar effects to si-UCHL3, as well as si-UCHL3+ si-NEDD8. Taken together, the results of the present study suggest that UCHL3 knockdown decreases melanoma cell proliferation by increasing cell autophagy through regulating NEDD8 expression and autophagosome numbers.

show abstract

Dual Immunotherapy in a Patient with Rapidly Progressive Metastatic Melanoma Without Failure of Grafted Kidney

et al. 2022

View full text Add to dashboard Cite

A 58-year-old female presented with a right axillary mass, which was confirmed as Stage IB BRAF-mutant melanoma based on the histology of the resected mass. The patient’s history included a left upper arm melanoma that was resected in 2012; an allograft renal transplant secondary to polycystic kidney disease from a deceased donor, which they had undergone in 2009; and immunosuppressive therapy, which they had been on since the transplant took place. The patient relapsed 8 months after axillary clearance. Dual immunotherapy is the first-line treatment for BRAF-mutant melanoma, but it has been associated with high rates of solid organ graft rejection in systematic reviews. For this reason, targeted therapy with dabrafenib and trametinib was commenced in the first instance, which halted disease progression for 10 months. On progression, dual immunotherapy was again discussed, and the patient fully consented regarding risks of graft loss. They had an excellent treatment response, and their renal graft remains functional.

show abstract

Melanoma in Solid Organ Transplant Recipients

Cited by 3 publications

References 59 publications

Post-transplant malignancies in solid organ recipients: development mechanisms and risk factors

Post-transplant malignancies in solid organ recipients: development mechanisms and risk factors

UCHL3 plays an important role in the occurrence and development of melanoma

Dual Immunotherapy in a Patient with Rapidly Progressive Metastatic Melanoma Without Failure of Grafted Kidney

Contact Info

Product

Resources

About